
Marksans Pharma Share Price
NSE: MARKSANS
|BSE: 524404
|Pharmaceuticals
₹254.55
-₹2.20 (-0.86%) Last updated on 11 Jul, 2025 | 15:59 ISTMarksans Pharma Overview
Market cap | Open ₹256.95 | Prev. Close ₹256.75 |
Circuit range ₹305.45 - ₹203.65 | Day range ₹253.50 - ₹266.00 | Year range ₹171.00 - ₹358.70 |
Volume 12,43,743 | Avg. traded ₹259.16 | Revenue (12m) ₹2,623 Crs |
About Marksans Pharma
Marksans Pharma Limited is a pharmaceutical company headquartered in Mumbai. Its primary focus is on over-the-counter (OTC) and prescription drugs with diverse applications in fields such as oncology, gastroenterology, antidiabetic, antibiotics, cardiovascular, pain management and gynaecology.
The market capitalisation of Marksans Pharma is over ₹7,300 crore as of January 11, 2024. Marksans Pharma share price has gained over 160% in the last three years.
Business operations
Marksans Pharma focuses on the distribution of pharmaceutical products and is actively involved in research and development (R&D). It provides contract research and manufacturing services (CRAMS) to global pharmaceutical companies. The company’s R&D capabilities include dossier development services, formulation development and specialised drug delivery systems.
In the domestic market, the company’s speciality division concentrates on oncology and critical care therapy, with Markparin and Epigrof being its most popular brands. Epigrof is also supplied to hospitals and other institutes specialising in burns and trauma care. The company has a cerebella division that specialises in marketing drugs for lifestyle diseases, neurology and psychiatric therapy.
Its primary markets include the US, Europe, Canada, Australia and emerging markets such as Southeast Asia, Africa, Latin America and Russia. Its product portfolio consists of over 500 registered products in these regions. These international operations have grown over the years due to mergers and acquisitions by the company.
Marksans Pharma acquired Nova Australasia Pty Ltd. (Nova) in 2005. Nova is an Australian marketing company specialising in the promotion of over-the-counter and pharmaceutical products. Following this, in 2008, Marksans expanded its portfolio through the acquisition of the UK's Hale Group, inclusive of its subsidiary company Bell, Sons & Co. (Druggists) Ltd. (Bell). In the same year, the company acquired Relonchem Ltd. This company is actively involved in the licensing, marketing and distribution of generic pharmaceutical products in the UK.
The company has a portfolio of more than 50 FDA-approved products. In the UK, it offers a diverse range of over 100 products under the Bells Healthcare brand and another 160 products under its Relonchem brand.
Marksans Pharma operates three manufacturing units located in different regions: Goa, the UK and the USA. In Farmingdale, USA, the company can produce 6 billion tablets and hard capsules annually. Meanwhile, the Southport unit in the UK contributes to the production of 2 billion bottles, 1 billion tubes and 1 billion sachets per year. In Goa, the manufacturing capabilities include 2.4 billion softgel and hard gelatin capsules annually, along with the production of 6 billion solid tablets per year. The plant in Goa is spread over 18,000 square metres.
In addition to its manufacturing facilities, Marksans Pharma Limited has four research and development (R&D) centres located in Goa, Navi Mumbai, the UK and the USA.
Financial Highlights
– Marksans Pharma’s revenue from operations for FY23 stood at ₹1,852 crore, up by 24.2% compared to ₹1,491 crore in FY22. – The net profit after tax for FY23 was ₹265.3 crore compared to ₹186.8 crore during the previous year. – In FY23, EBITDA increased to ₹339.3 crore from the previous year's ₹258.9 crore. – The company's earnings per share (EPS) stood at ₹6.4 in FY23 compared to ₹4.5 in the previous financial year.
Marksans Pharma Share Price Chart
Marksans Pharma Key Indicators
P/E ratio 30.3 | P/B ratio 4.74 | ROE 11.46% |
ROCE 14.81% | Dividend yield 0.31% | Debt/Equity ratio |
EPS 2.95 |
Investment Checklist: (4/6)
Equity returns
Dividend returns
Safety factor
Growth factor
Debt vs Equity
Profit factor
The investment checklist helps you understand a company's financial health at a glance and identify quality investment opportunities easily
Analyst Ratings:
100%
Hold
0%
Sell
0%
This analysis is based on the reviews of 2 experts in the last 7 days
Marksans Pharma Financial Ratios
Operating profit margin23.61% | Net profit margin15.63% |
ROE11.46% | ROA9.17% |
ROCE14.81% |
Quick ratio2.59 | Current ratio3.22 |
Interest coverage174.98 | Asset turnover0.59 |
Debt to Equity0 |
P/E ratio30.3 | P/B ratio4.74 |
EV / EBITDA32.45 | |
Dividend yield0.31% |
Revenue Statement
Year | Revenue | Operating Profit | Net Profit |
---|---|---|---|
Mar-24 | ₹2,177.41 | ₹509.00 | ₹314.89 |
Mar-23 | ₹1,852.14 | ₹398.63 | ₹265.32 |
Mar-22 | ₹1,490.84 | ₹300.73 | ₹186.81 |
Mar-21 | ₹1,376.18 | ₹346.30 | ₹238.54 |
Cash Flow
Year | Operating | Investing | Financing |
---|---|---|---|
Mar-24 | ₹-140.84 | ₹-68.73 | |
Mar-23 | ₹-259.21 | ||
Mar-22 | ₹-84.39 | ||
Mar-21 | ₹-44.85 | ₹-15.29 |
Balance Sheet
Period | Total Asset | Total Liability |
---|---|---|
Mar-24 | ₹2,680.95 | ₹595.05 |
Mar-23 | ₹2,190.39 | ₹425.32 |
Mar-22 | ₹1,660.11 | ₹437.14 |
Mar-21 | ₹1,228.02 | ₹322.67 |
Marksans Pharma Share Price History
Day | Open | Close | Change % |
---|---|---|---|
11-Jul-25 | ₹256.95 | ₹254.55 | -0.86% |
10-Jul-25 | ₹259.00 | ₹256.75 | -0.81% |
09-Jul-25 | ₹253.05 | ₹258.85 | |
08-Jul-25 | ₹257.50 | ₹252.45 | -1.92% |
07-Jul-25 | ₹263.30 | ₹257.40 | -2.15% |
04-Jul-25 | ₹260.05 | ₹263.05 | |
03-Jul-25 | ₹258.20 | ₹259.50 | |
02-Jul-25 | ₹258.00 | ₹257.35 | -0.44% |
Corporate Actions
Dividend • ₹0.6/share
Ex date 17 Sep 2024
Stocks Similar to Marksans Pharma
Stock Name | Price | Change % |
---|---|---|
Alembic | ₹117.26 | -₹1.46 (-1.23%) |
Amrutajan Health | ₹726.40 | -₹9.85 (-1.34%) |
Gufic Biosciences | ₹349.90 | -₹1.30 (-0.37%) |
Hester Biosciences | ₹1,800.00 | +₹5.50 (0.31%) |
Morepen Labs | ₹62.67 | -₹0.80 (-1.26%) |
Neuland Lab | ₹12,301.00 | +₹421.00 (3.54%) |
Unichem Laboratories | ₹590.25 | -₹7.15 (-1.2%) |
Popular Stocks
Stock Name | Price | Change % |
---|---|---|
IDFC First Bank | ₹75.23 | -₹1.40 (-1.83%) |
Indian Railway Finance Corp | ₹135.28 | -₹1.85 (-1.35%) |
ITC | ₹416.80 | -₹0.05 (-0.01%) |
JIO FIN SERVICES LTD | ₹325.80 | -₹5.85 (-1.76%) |
Suzlon | ₹65.92 | -₹0.05 (-0.08%) |
Tata Motors | ₹681.80 | -₹13.80 (-1.98%) |
Tata Power | ₹396.85 | -₹3.05 (-0.76%) |
Tata Steel | ₹159.84 | -₹0.82 (-0.51%) |
Trident | ₹31.70 | -₹0.39 (-1.22%) |
Wipro | ₹258.30 | -₹6.75 (-2.55%) |